The prospects for the development of Russian nuclear medicine were discussed in the State Duma. What role does NMIC of Radiology play?

On April 11, Director of the A.F. Tsyba MRSC – branch of the NMIC of Radiology of the Ministry of Health of the Russian Federation, Corresponding Member of the Russian Academy of Sciences Sergey Ivanov and Valery Krylov – Head of the Department of Radiosurgical treatment with open radionuclides of the A.F. Tsyba MRSC, took part in a round table of the State Duma Committee on Health Protection devoted to topical issues of the development of nuclear medicine.

Undoubtedly, the development of this area of diagnosis and treatment of non–communicable diseases, including cancer, today occupies a leading place on the agenda of the organization of the healthcare system not only in Russia, but also in the world. The nuclear medicine market is developing rapidly, according to analysts, the global market volume will grow to $43 billion by 2030. Traditionally, two segments are distinguished – diagnostic and therapeutic, but recently theranostics has been developed – the synthesis of diagnostic procedures and simultaneous treatment.

NMIC of Radiology of the Ministry of Health of Russia today is a “testing ground” for the development and testing of the latest domestic radiopharmaceuticals, paying considerable attention not only to the scientific, but also to the practical component of the process of introducing new technologies into life, which was the subject of the speech of Director Sergey Ivanov.

The year 2022 was a breakthrough for domestic medicine. The first nuclear pharmacy in a medical institution on the territory of the Russian Federation was opened in the MRSC named after A.F. Tsyba. It synthesizes innovative radiopharmaceuticals based on radionuclides developed on the basis of the Center: rhenium, and lutetium, and actinium. They treat patients with metastatic prostate cancer, primary and secondary liver cancer, metastatic lesions of the skeleton and liver, as well as those suffering from chronic knee synovitis. In addition, in the future, the RFLP pharmacy is supposed to manufacture drugs for the treatment of neuroendocrine malignant neoplasms and non-Hodgkin’s lymphoma.

Andrey Kaprin, Director General of the NMIC of Radiology of the Ministry of Health of Russia, Academician of the Russian Academy of Sciences, also emphasizes: “Nuclear medicine is a promising area that is rapidly developing thanks to the support of the Ministry of Health of Russia. And when such treatment is competently combined with surgical and chemotherapeutic, we get the cruelest enemy of tumor cells.”

Press Service of the NMIC of Radiology of the Ministry of Health of Russia